No. | Hazard ratio | P | ||
---|---|---|---|---|
(95% CI) | ||||
Univariate analysis | ||||
Gender | ||||
Male | 142 | 0.40 | ||
Female | 53 | |||
Age (y) | ||||
<60 | 84 | 0.12 | ||
≥60 | 111 | |||
Tumor differentiation | ||||
Well | 12 | 0.74 | ||
Moderate | 27 | |||
Poor | 156 | |||
Tumor size (cm) | ||||
<4.5 | 114 | 0.03 | ||
≥4.5 | 81 | |||
TNM stage | ||||
I–II | 136 | 0.88 | ||
III | 59 | |||
Her-2 status | ||||
Negative | 164 | 0.12 | ||
Positive | 31 | |||
Primary/Recurrent | ||||
Primary tumor | 116 | <0.01 | ||
Recurrent tumor | 79 | |||
eIF3f expression | ||||
Low | 129 | 0.04 | ||
High | 66 | |||
Multivariate analysis | ||||
Tumor size (cm) | ||||
<4.5 | 114 | 2.31 | 0.04 | |
≥4.5 | 81 | 1.04–5.11 | ||
Primary/Recurrent | ||||
Primary tumor | 116 | 3.77 | <0.01 | |
Recurrent tumor | 79 | 1.79–7.94 | ||
eIF3f expression | ||||
Low | 129 | 2.27 | 0.04 | |
High | 66 | 1.05–4.92 |